The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in italian patients

Benucci M, Li Gobbi F, Sabadini L, Saviola G, Baiardi P, Manfredi M

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
20074482

Indexing Status
Subject indexing assigned by NLM

MeSH
Adalimumab; Antibodies, Monoclonal /administration & dosage /economics; Antibodies, Monoclonal, Humanized; Antirheumatic Agents /administration & dosage /economics; Arthritis, Rheumatoid /drug therapy /economics /immunology; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Etanercept; Humans; Immunoglobulin G /administration & dosage /economics; Injections, Subcutaneous; Isoxazoles /administration & dosage; Italy; Methotrexate /administration & dosage; Models, Economic; Patient Selection; Quality-Adjusted Life Years; Receptors, Tumor Necrosis Factor /administration & dosage; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha /antagonists & inhibitors

AccessionNumber
22010000569

Date bibliographic record published
18/08/2010